Ketamine One (NEO:MEDI.AQN) Interim CEO Adam Deffett joined Steve Darling to share news the company is launching a single-arm, open-label study of patients with post-traumatic stress disorder who are undergoing the Company’s IRP Health clinics. The company is also doing an observational, single-arm, pilot study aimed at collecting biometric data and validated psychiatric instrument measures of efficacy in patients with depression symptoms who are receiving IV ketamine infusion therapy.
Deffett telling Proactive the launch of these studies is a big milestone for the company and shows the evolving relationship between KGK Science and IRP Health.